Dudi Klein

NEW HOPE IN BLADDER CANCER TREATMENT Vessi Medical is an Israeli medical device startup that brings a new approach to treat Non-Muscle-Invasive Bladder Cancer (NMIBC). The Company uses surface cryotherapy, a treatment that utilizes extreme cold, to freeze and destroy abnormal tissue. THE LEADING STANDARD OF CARE, TURBT, HAS NUMEROUS LIMITATIONS Categorized as surface cancer on the inside lining of the bladder, NMIBC affects 2 million people globally with 300,000 new cases reported every year. TransUrethral Resection of Bladder Tumor (TURBT) is the leading first-line therapy. Yet, this invasive surgical procedure, performed under general anesthesia and requiring a costly hospital stay, can often be inadequate. In up to 80% of cases the cancer returns, with increased complications as patients need multiple repeat procedures that further reduce quality of life. VESSI PROVIDES A NEW FIRST-LINE, OFFICE-BASED THERAPY ALTERNATIVE TO SURGERY Vessis minimally invasive NMIBC solution provides a new, first-line, office-based therapy alternative to surgery. The companys patent-pending, bladder-specific cryotherapy technology eliminates costly and problematic repeat surgeries seen with TURBT. The technology successfully ablates unwanted tissue, reduces the risk of dispersed cancers cells, all while causing no bladder damage. The Vessi system consists of a standalone console and a disposable catheter that is inserted into the bladder. CHANGING THE STANDARD OF CARE IN BLADDER CANCER Vessi is backed by the Trendlines Group, a leading Israeli early stage investor, and led by seasoned medical device and cryotherapy veterans. The company has already demonstrated promising proof of concept in animals with its Alpha product. Vessi’s first application will initially target the $1.2 billion NMIBC market, with future applications for the treatment of overactive bladder and urinary tract infections, both billion-dollar markets. For more information, please email eyal@vessimed.com.

The Append Medical system is designed to prevent blood clot leakage by achieving complete LAA closure thus reducing the risk of stroke in patients with non-valvular atrial fibrillation. Its unique design may allow it to mitigate device-related thromboembolism risk by leaving minimal foreign material at the closure site. The procedure itself is intended to be simple, fast and requiring less pre-procedure planning.

Navina was born with the vision to create a new world where the time-consuming chaos of patient data is replaced by a logical actionable platform that makes it possible for every physician to assess even the most complex cases in minutes. Our technology creates a new era of simplicity by restructuring disorganized data into an intelligible patient portrait, intuitively organized for sophisticated and empathetic patient care. We use AI and machine learning to make sure that whats most important is immediately clear, diagnostically linked, and contextually surfaced, so physicians can have the entirety of each patient’s data. The result: optimum patient wellness and enhanced financial performance for providers and payers. Navina is a partner of the American Academy of Family Physicians (AAFP) Innovation Lab.

OncoHost is a technology company transforming the approach to precision medicine for improved patient outcomes. OncoHost’s proprietary platform, PROphet®, is a plasma-based, proteomic pattern analysis tool whose initial offering in non-small cell lung cancer (NSCLC) uses a single blood sample to guide first-line immunotherapy decision-making. The PROphet® NSCLC test provides clear clinical utility by offering physicians crucial guidance on the optimal first-line immunotherapy treatment plan for each individual patient, with a significant effect on overall survival. Led by an experienced team of entrepreneurs and industry experts and supported by a large-scale prospective clinical trial with over 40 sites and 1,700 patients recruited worldwide, OncoHost is well-positioned to lead precision diagnostics and biomarker development to the next stage.

Women's health | Early detection | Femtech | Frost&Sullivan Innovation award winner | Masschallenge First Place Winner

The growing number of connected medical devices in hospital networks has introduced a new breed of threats that healthcare organizations cannot address with IT cybersecurity solutions. Cynerio’s mission is to empower healthcare CISOs and give them full control over the security of their connected clinical engineering and IoT ecosystem, ensuring data protection, service continuity and patient safety. With Cynerio’s solution, security teams can see which medical and IoT devices are connected, understand their associated risks, and protect against harmful cyber-attacks.

At Medisafe®, our mission is to be the worlds leading medication management platform, dedicated to engaging patients and putting them in control of their healthcare journey. We empower individuals to take charge of their health by providing a comprehensive solution that encompasses appointments, symptoms, measurements, reports, trials, connection with care teams and much more. Through the fusion of advanced technology and behavior science, Medisafe reimagines the treatment journey, offering personalized guidance tailored to each patients specific needs. Our digital technology forms the foundation of a holistic patient engagement platform, delivering scalable support that is customized to individuals in a meaningful way. By integrating existing patient support programs into our platform, we revolutionize the future model of patient care, resulting in improved health outcomes. With more than 10 million registered patients and caregivers relying on our platform, we have successfully delivered double-digit improvements in patient outcomes. Medisafe manages an astonishing two billion medication doses through iOS and Android smartphones and tablets. Our commitment to excellence is reflected in our average rating of 4.7 out of 5 stars and over 400,000 ratings and reviews. Medisafe fosters daily engagement rate that surpasses popular social media applications like Facebook or Twitter. As a HIPAA and GDPR compliant solution, we prioritize the security and privacy of our users data. Moreover, our ISO 27001:2013 and ISO 13485:2016 certifications underscore our dedication to maintaining the highest standards of quality and safety. At Medisafe, we strive to empower patients, enhance their healthcare experience, and ultimately improve their overall well-being.

NEW HOPE IN BLADDER CANCER TREATMENT Vessi Medical is an Israeli medical device startup that brings a new approach to treat Non-Muscle-Invasive Bladder Cancer (NMIBC). The Company uses surface cryotherapy, a treatment that utilizes extreme cold, to freeze and destroy abnormal tissue. THE LEADING STANDARD OF CARE, TURBT, HAS NUMEROUS LIMITATIONS Categorized as surface cancer on the inside lining of the bladder, NMIBC affects 2 million people globally with 300,000 new cases reported every year. TransUrethral Resection of Bladder Tumor (TURBT) is the leading first-line therapy. Yet, this invasive surgical procedure, performed under general anesthesia and requiring a costly hospital stay, can often be inadequate. In up to 80% of cases the cancer returns, with increased complications as patients need multiple repeat procedures that further reduce quality of life. VESSI PROVIDES A NEW FIRST-LINE, OFFICE-BASED THERAPY ALTERNATIVE TO SURGERY Vessis minimally invasive NMIBC solution provides a new, first-line, office-based therapy alternative to surgery. The companys patent-pending, bladder-specific cryotherapy technology eliminates costly and problematic repeat surgeries seen with TURBT. The technology successfully ablates unwanted tissue, reduces the risk of dispersed cancers cells, all while causing no bladder damage. The Vessi system consists of a standalone console and a disposable catheter that is inserted into the bladder. CHANGING THE STANDARD OF CARE IN BLADDER CANCER Vessi is backed by the Trendlines Group, a leading Israeli early stage investor, and led by seasoned medical device and cryotherapy veterans. The company has already demonstrated promising proof of concept in animals with its Alpha product. Vessi’s first application will initially target the $1.2 billion NMIBC market, with future applications for the treatment of overactive bladder and urinary tract infections, both billion-dollar markets. For more information, please email eyal@vessimed.com.

The Append Medical system is designed to prevent blood clot leakage by achieving complete LAA closure thus reducing the risk of stroke in patients with non-valvular atrial fibrillation. Its unique design may allow it to mitigate device-related thromboembolism risk by leaving minimal foreign material at the closure site. The procedure itself is intended to be simple, fast and requiring less pre-procedure planning.

Navina was born with the vision to create a new world where the time-consuming chaos of patient data is replaced by a logical actionable platform that makes it possible for every physician to assess even the most complex cases in minutes. Our technology creates a new era of simplicity by restructuring disorganized data into an intelligible patient portrait, intuitively organized for sophisticated and empathetic patient care. We use AI and machine learning to make sure that whats most important is immediately clear, diagnostically linked, and contextually surfaced, so physicians can have the entirety of each patient’s data. The result: optimum patient wellness and enhanced financial performance for providers and payers. Navina is a partner of the American Academy of Family Physicians (AAFP) Innovation Lab.

OncoHost is a technology company transforming the approach to precision medicine for improved patient outcomes. OncoHost’s proprietary platform, PROphet®, is a plasma-based, proteomic pattern analysis tool whose initial offering in non-small cell lung cancer (NSCLC) uses a single blood sample to guide first-line immunotherapy decision-making. The PROphet® NSCLC test provides clear clinical utility by offering physicians crucial guidance on the optimal first-line immunotherapy treatment plan for each individual patient, with a significant effect on overall survival. Led by an experienced team of entrepreneurs and industry experts and supported by a large-scale prospective clinical trial with over 40 sites and 1,700 patients recruited worldwide, OncoHost is well-positioned to lead precision diagnostics and biomarker development to the next stage.

Women's health | Early detection | Femtech | Frost&Sullivan Innovation award winner | Masschallenge First Place Winner